MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma (NCT00020579) | Clinical Trial Compass
CompletedPhase 1
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
United States75 participantsStarted 2001-03
Plain-language summary
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth.
PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid tumors or lymphoma.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Histologically confirmed malignancy that is metastatic or unresectable and for which no effective standard curative or palliative therapy exists
* Brain metastases allowed provided both of the following criteria are met:
* Received treatment for the brain metastases
* Stable for ≥ 6 months without steroids or antiseizure medications
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* ECOG 0-2 OR
* Karnofsky 50-100%
Life expectancy:
* More than 3 months
Hematopoietic:
* WBC at least 3,000/mm\^3
* Absolute neutrophil count at least 1,500/mm\^3
* Platelet count at least 100,000/mm\^3
Hepatic:
* Bilirubin no greater than 1.5 times upper limit of normal (ULN) (≤ 3 mg/dL for patients with Gilbert's syndrome)
* AST/ALT no greater than 2.5 times ULN
* Albumin at least 75% of lower limit of normal
Renal:
* Creatinine normal OR
* Creatinine clearance at least 60 mL/min
Cardiovascular:
* Cardiac ejection fraction normal by MUGA
* No symptomatic congestive heart failure
* No unstable angina pectoris
* No cardiac arrhythmia
Other:
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* Adequate oral intake
* No weight loss of more than 10% of actual body weight within the past 2 months
* No history of allergic reaction to compounds of similar chemical or biological composition to study drug
* No other uncontrolled illness
* No ongoing or active infection
* No seizure disorder
…
What they're measuring
1
Dose-limiting toxicities and maximum tolerated dose
2
Pharmacology and pharmacokinetics
Trial details
NCT IDNCT00020579
SponsorNational Institutes of Health Clinical Center (CC)